Market research
LUMO Lumos Pharma Inc
NASDAQ USD Healthcare
Latest close
As of 09 Jan 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 38M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 0.33
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 38M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 0.33
About
About Lumos Pharma Inc
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.
Research context
Lumos Pharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LUMO discussion.
5 years, 7 months ago
Lumos Pharma, Inc is currently in a long term downtrend where the price is trading 35.1% below its 200 day moving average.
From a valuation standpoint, the stock is 63.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 494.2.
Lumos Pharma, Inc's total revenue sank by 90.8% to $40K since the same quarter in the previous year.
Its net income has increased by 70.8% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.9% to $-7M since the same quarter in the previous year.
Based on the above factors, Lumos Pharma, Inc gets an overall score of 3/5.